Cross-reactivity of TDX and OPUS immunoassay systems for serum digoxin determination

Mamie Okazaki, Yusuke Tanigawara, Tomoko Kita, Fusao Komada, Katsuhiko Okumura

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The properties of the widely used TDX Analyzer and recently developed OPUS Immunoassay System were compared using 403 serum specimens taken from patients who did or did not take digoxin. Of the 210 specimens from patients not treated with digoxin, a false-positive digoxin concentration was detected in 15 specimens (7%) by TDX and in only 2 specimens (1%) by OPUS because of the cross-reactivity with structurally similar drugs. Potassium canrenoate, digitoxin, deslanoside, and methyldigoxin exhibited marked concentration- dependent cross-reactivity in the TDX assay method, whereas deslanoside and methyldigoxin only showed cross-reactivity with the antibody used in the OPUS method. Although a poor correlation was observed between these two methods for the determination of 193 samples from patients treated with digoxin, the correlation was remarkably improved (r = 0.914) and the slope approximated unity when excluded the data from patients who were treated concurrently with the cross-reactive compounds. In routine TDM of digoxin, the authors experienced two cases in which cross-reactivity of the assay system caused a clinical problem. Concurrent administration of intravenous canrenoate apparently interfered with the digoxin assay by TDX, but this problem was solved by using the OPUS system. The authors found OPUS more useful for monitoring serum digoxin concentrations in patients because of its superior specificity.

Original languageEnglish
Pages (from-to)657-662
Number of pages6
JournalTherapeutic Drug Monitoring
Volume19
Issue number6
DOIs
Publication statusPublished - 1997 Dec 1
Externally publishedYes

    Fingerprint

Keywords

  • Canrenoate
  • Cross-reactivity
  • Digoxin
  • FPIA
  • OPUS

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this